Etentamig for Newly Diagnosed Patients

Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Near Add Your Location

Sorting 15 by

Weill Cornell
New York, NY
  • Accepting patients
Minnesota Oncology
Minneapolis, MN
  • Accepting patients
UNC Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
  • Accepting patients
Virginia Cancer Specialists
Fairfax, VA
  • Accepting patients
Texas Oncology
Tyler, TX
  • Accepting patients
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.